Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients

Bibliographic Information
Authors: El-Khayat H.; Kamal E.M.; Yakoot M.; Gawad M.A.; Kamal N.; El Shabrawi M.; Sameh Y.; Haseeb A.; Fouad Y.; Attia D.
Journal: European Journal of Gastroenterology and Hepatology
Publisher: Lippincott Williams and Wilkins
Publication Date: August 2019
Volume / Issue: Volume 31 / Issue 8
Pages: 1004–1009
ISSN: 0954691X
DOI: 10.1097/MEG.0000000000001360
Scopus: View on Scopus
PubMed: 30676473
Document Type: Article
Authors and Affiliations
El-Khayat H., Department of Gastroenterology Hepatology and Endemic Medicine, Theodore Bilharz Research Institute, Egypt; Kamal E.M., Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, Minia, Egypt; Yakoot M., Green Clinic Research Centre, Alexandria, Egypt; Gawad M.A., Pediatrics and Pediatrics Hepatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Kamal N., Pediatric and Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; El Shabrawi M., Pediatric and Pediatrics Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt; Sameh Y., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Haseeb A., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Fouad Y., Department of Gastroenterology, Hepatology and Endemic Medicine, Minia University Hospitals, Minia, Egypt; Attia D., Department of Hepatology, Gastroenterology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
Abstract
BackgroundThe sustained virological response (SVR) rate for the 12-week sofosbuvir (SOF)/ledipasvir (LVD) treatment of adolescent genotype-4 patients is high. The aim of this study is to evaluate 8 versus 12-week treatment efficacy and safety in adolescent genotype-4 patients.Patients and methodsIn total, 157 chronic hepatitis C-infected adolescent patients (mean age 14±2 years, 62% males) were included in this study. All patients received a morning dose of SOF (400 mg)/LVD (90 mg) as a single tablet for 8 and 12 weeks. Laboratory and biochemical monitoring were performed at weeks 4 and 8, end of treatment (8/12) and 12 weeks after the end of treatment (SVR12).ResultsIn total, SVR12 was 98% [95% confidence interval (CI): 96-100] for all treated patients. For patients treated for 12 weeks, SVR12 was 97.6% (95% CI: 96-101) (82/84 patients), and 98.6% (95% CI: 93-101) (72/73) patients for those treated for 8 weeks. For both regimens, no serious adverse effects, treatment discontinuation or cases of death were detected. The main adverse effects for the 8-week patient group were fatigue (2.8%), headache (1.4%), nausea (1.4%) and epigastric tenderness (1.4%). For the 12-week-treated group, adverse events were epigastric tenderness (1.2%), nausea (1.2%), diarrhoea (2.4%) and rash (2.4%). Three patients were lost to follow-up: Two were in the 12-week treatment group and one was in the 8-week group. All of them reached end of treatment but were lost before SVR12. No relapsers were observed in either group.ConclusionEight weeks of treatment of SOF/LVD combination is equally effective and safe as 12 weeks in adolescent genotype-4 patients. © 2019 Lippincott Williams and Wilkins. All rights reserved.
Keywords
12-17 years old; direct-acting antivirals; GT-4; hepatitis C virus; SVR12; Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Elasticity Imaging Techniques; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver; Male; Prospective Studies; Treatment Outcome; Uridine Monophosphate; ledipasvir plus sofosbuvir; antivirus agent; benzimidazole derivative; fluorene derivative; ledipasvir, sofosbuvir drug combination; uridine phosphate; abdominal tenderness; antiviral therapy; Article; chronic hepatitis C; clinical effectiveness; cross-sectional study; drug safety; drug withdrawal; fatigue; follow up; headache; human; major clinical study; morning dosage; nausea; priority journal; prospective study; treatment duration; diagnostic imaging; dose response; drug administration; elastography; oral drug administration; procedures
Citation Information
Scopus Citations: 17
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
